Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 9/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4961044 | 0.89 | ALDH1A1 (0.48) | LMNAMAPTGAANAMPTPOLB | |
| SCHEMBL2894559 | 0.89 | ALDH1A1 (0.47) | LMNAMAPTGAAPOLBALDH1A1 | |
| SCHEMBL1208434 | 0.84 | MAPT (0.48) | LMNAMAPTGAANAMPTCYP3A4 | |
| SCHEMBL4960071 | 0.84 | TP53 (0.43) | LMNAMAPTGAACYP3A4CYP2C9 | |
| SCHEMBL4961190 | 0.84 | SMN1; SMN2 (0.48) | LMNAMAPTGAAPOLBALDH1A1 | |
| SCHEMBL4961200 | 0.84 | ALDH1A1 (0.41) | LMNAMAPTGAAPOLBALDH1A1 | |
| SCHEMBL2895762 | 0.83 | APEX1 (0.43) | LMNAMAPTGAACYP3A4CYP2C9 | |
| SCHEMBL4964396 | 0.83 | MAPK10 (0.46) | LMNAMAPTGAAPOLBALDH1A1 | |
| SCHEMBL4960969 | 0.82 | ALDH1A1 (0.42) | LMNAMAPTGAAPOLBALDH1A1 | |
| SCHEMBL1207838 | 0.82 | ALDH1A1 (0.51) | LMNAMAPTGAANAMPTCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100285149-A1 | NOVEL TETRAHYDROPYRIDOTHIOPHENES | 4SC AG (DE) | 2010-11-11 | — | — | US | disclosed |
| EP-1797094-A4 | 1,3-DISUBSTITUTED HETEROARYL NMDA/NR2B ANTAGONISTS | MERCK & CO INC (US) | 2009-06-03 | — | — | EP | disclosed |
| EP-2051983-A1 | NTETRAHYDROPYRIDOTHIOPHENE DERIVATIVES FOR THE TREATMENT OF CANCER | 4SC AG (DE) | 2009-04-29 | — | — | EP | disclosed |
| EP-1896484-A2 | TETRAHYDROPYRIDOTHIOPHENES FOR USE IN THE TREATMENT OF CANCER | Nycomed GmbH (DE) | 2008-03-12 | — | — | EP | disclosed |
| WO-2008020024-A1 | NTETRAHYDROPYRIDOTHIOPHENE DERIVATIVES FOR THE TREATMENT OF CANCER | 4SC AG (DE) | 2008-02-21 | — | — | WO | disclosed |
| EP-1797094-A2 | 1,3-DISUBSTITUTED HETEROARYL NMDA/NR2B ANTAGONISTS | Merck & Co. Inc. (US) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006125813-A2 | TETRAHYDROPYRIDOTHIOPHENES FOR USE IN THE TREATMENT OF CANCER | NYCOMED GMBH (DE) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006017409-A2 | 1,3-DISUBSTITUTED HETEROARYL NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100285149-A1 | NOVEL TETRAHYDROPYRIDOTHIOPHENES | BAX, CCAR2, BCL2 | LMNA 3689/4885MAPT 1389/4885GAA 4376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.